CollPlant names CFO Eran Rotem CEO, replacing Yehiel Tal
CLGN•CollPlant Biotechnologies appointed Deputy CEO and CFO Eran Rotem as CEO, replacing Yehiel Tal, effective November 2, 2026. Tal also resigned as interim board chairman, as the company pursues cost reductions that include discontinuing regenerative medicine research and development.
1. Leadership change
CollPlant Biotechnologies appointed Deputy CEO and Chief Financial Officer Eran Rotem as CEO, replacing Yehiel Tal, effective November 2, 2026. Tal also resigned as interim board chairman on that date. The leadership change is part of a broader cost-reduction plan that includes discontinuing regenerative medicine research and development.
